Lantern Pharma up on FDA's rare pediatric disease tag for cancer therapy

Lantern Pharma

23/09/2024 15:32

** Shares of Lantern Pharma  LTRN.O  rise 2% to $4.07  
    ** Co says the U.S. FDA has granted three rare pediatric
disease (RPD) tags to its experimental cancer therapy, LP-184
    ** LTRN says has been granted the RPD designations in three
rare pediatric cancers: malignant rhabdoid tumors,
rhabdomyosarcoma, and hepatoblastoma
    ** FDA grants RPD designation to drugs that treat certain
serious or life-threatening diseases that primarily affect
children and fewer than 200,000 people in the United States
    ** Including session gains, stock down ~3% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))